How CJC-1295 No-DAC Affects Fasting Glucose

CJC-1295 no-DAC (modified GRF 1-29) amplifies pulsatile GH release by binding the GHRH receptor on pituitary somatotrophs. Its short plasma half-life of approximately 30 minutes confines each GH pulse to a discrete 2 to 3 hour window. The glucose impact is therefore a transient phenomenon rather than a sustained metabolic burden.

1. GH-mediated post-injection glucose transient: The GH pulse triggered by each CJC-1295 no-DAC injection promotes hepatic gluconeogenesis and reduces peripheral glucose uptake in muscle and adipose tissue via IRS-1 phosphorylation impairment. This produces a mild, transient rise in blood glucose lasting 1 to 3 hours post-injection.
2. Recovery between pulses: Once GH returns to baseline, insulin signalling normalises rapidly. With standard dosing schedules of 1 to 3 injections per day, each inter-pulse interval allows full insulin sensitivity recovery. This pulsatile pattern is the mechanistic contrast with MK-677, whose 24-hour GH elevation maintains continuous anti-insulin pressure without recovery windows.
3. Amplification via GHRP co-injection: CJC-1295 no-DAC is almost always co-administered with ipamorelin. The combined pulse is larger than either compound alone, producing a modestly larger but still transient glucose transient. Inter-dose insulin sensitivity recovery remains intact.
4. Lipolytic FFA contribution: GH pulses promote lipolysis, releasing free fatty acids (FFAs) that compete with glucose for uptake via the Randle cycle. This FFA-driven component contributes to the transient post-injection insulin resistance, but resolves as FFA levels normalise between pulses.

No controlled human trial has directly measured fasting glucose for the CJC-1295 no-DAC plus ipamorelin combination. The mechanistic expectation of near-neutral fasting glucose is supported by the pulsatile GHRH-class pharmacology and by tesamorelin Phase 3 data (Falutz et al., 2010, PMID 20554713), which found no statistically significant fasting glucose change across 806 patients over 26 to 52 weeks of daily GHRH-analog dosing.

Standard combined protocol (100 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin, 1-2 times daily):

• Fasting glucose: typically unchanged or mildly elevated by 0.1 to 0.2 mmol/L (2 to 4 mg/dL) at most
• HbA1c: no clinically significant change expected; tesamorelin (daily GHRH analog) showed no glucose change over 52 weeks (Falutz 2010)
• Post-injection glucose (30 to 90 minutes after): may transiently rise 0.3 to 0.8 mmol/L (5 to 15 mg/dL) during the GH pulse; typically undetectable on standard fasting blood work drawn away from injection times
• Fasting insulin: no significant change expected; compare with MK-677, which raises fasting insulin substantially

Comparison with MK-677 (25 mg/day):

• MK-677 raised fasting glucose 0.3 mmol/L and HbA1c 0.2% in a 2-year RCT (Nass et al., 2008, PMID 18981485), with 37% of subjects shifting toward pre-diabetic glucose levels
• CJC-1295 no-DAC plus ipamorelin at standard doses produces a fraction of this metabolic burden

Timeline: Any transient glucose effects begin with the first injection. No cumulative fasting glucose drift is expected on standard dosing protocols based on GHRH-class clinical data.

Baseline: Obtain fasting glucose and HbA1c before starting. Document any pre-existing insulin resistance or family history of type 2 diabetes.

During use:

• Fasting glucose and HbA1c every 6 months on a long-term protocol
• Increase to quarterly if stacking with compounds that independently elevate glucose: MK-677, exogenous GH, AAS (particularly oxandrolone, oxymesterone, or high-dose testosterone)
• If baseline fasting glucose is above 5.5 mmol/L (99 mg/dL), monitor quarterly from the start

Key advantage: The monitoring burden for CJC-1295 no-DAC is substantially lower than for MK-677 or exogenous GH. Semi-annual fasting glucose is appropriate for most users without metabolic risk factors.

Timing note: If testing within 2 to 3 hours of an injection, glucose may be transiently elevated from the GH pulse. For accurate fasting glucose measurement, draw blood at least 3 to 4 hours after the most recent injection, or in the morning before the first injection of the day.

If baseline metabolic risk is present:

• Inject in a fasted state (30 minutes before food) to maximise GH pulse amplitude and minimise any glucose interaction from concurrent carbohydrate intake
• Limit total GH peptide load by keeping to 1 to 2 injections per day rather than 3
• Avoid stacking with MK-677 if fasting glucose is already borderline

If fasting glucose rises above 5.5 mmol/L (99 mg/dL) on a CJC-1295 no-DAC protocol:

• Audit for other drivers before attributing to the peptide: AAS use, caloric surplus, reduced activity, MK-677 co-use, sleep deprivation
• Berberine 500 mg twice daily with meals is a conservative intervention if glucose creep is confirmed
• Metformin is generally not warranted for CJC-1295 no-DAC users without independent metabolic disease

Cycle management:

• Standard bodybuilding protocols run 3 to 6 months on, 1 to 2 months off
• Glucose typically remains unchanged throughout on-cycle periods and returns to exact baseline off-cycle
• No insulin sensitiser taper is required on discontinuation, unlike MK-677